These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17308886)

  • 21. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
    Sun B; Fredrickson K; Austin S; Tolun AA; Thurberg BL; Kraus WE; Bali D; Chen YT; Kishnani PS
    Mol Genet Metab; 2013 Feb; 108(2):145-7. PubMed ID: 23318145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycogen storage diseases: new perspectives.
    Ozen H
    World J Gastroenterol; 2007 May; 13(18):2541-53. PubMed ID: 17552001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
    Chou JY; Jun HS; Mansfield BC
    J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease.
    Kanters TA; Hoogenboom-Plug I; Rutten-Van Mölken MP; Redekop WK; van der Ploeg AT; Hakkaart L
    Orphanet J Rare Dis; 2014 May; 9():75. PubMed ID: 24884717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
    Banugaria SG; Prater SN; Patel TT; Dearmey SM; Milleson C; Sheets KB; Bali DS; Rehder CW; Raiman JA; Wang RA; Labarthe F; Charrow J; Harmatz P; Chakraborty P; Rosenberg AS; Kishnani PS
    PLoS One; 2013; 8(6):e67052. PubMed ID: 23825616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.
    Sun B; Kulis MD; Young SP; Hobeika AC; Li S; Bird A; Zhang H; Li Y; Clay TM; Burks W; Kishnani PS; Koeberl DD
    Mol Ther; 2010 Feb; 18(2):353-60. PubMed ID: 19690517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
    Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
    Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control.
    Dambska M; Labrador EB; Kuo CL; Weinstein DA
    Pediatr Diabetes; 2017 Aug; 18(5):327-331. PubMed ID: 28568353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy for glycogen storage diseases.
    Kishnani PS; Sun B; Koeberl DD
    Hum Mol Genet; 2019 Oct; 28(R1):R31-R41. PubMed ID: 31227835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic glycogen storage disorders: what have we learned in recent years?
    Burda P; Hochuli M
    Curr Opin Clin Nutr Metab Care; 2015 Jul; 18(4):415-21. PubMed ID: 26001652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical and clinical aspects of glycogen storage diseases.
    Ellingwood SS; Cheng A
    J Endocrinol; 2018 Sep; 238(3):R131-R141. PubMed ID: 29875163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of a human induced pluripotent stem cell line, BRCi009-A, derived from a patient with glycogen storage disease type 1a.
    Katagami Y; Kondo T; Suga M; Yada Y; Imamura K; Shibukawa R; Sagara Y; Okanishi Y; Tsukita K; Hirayama K; Era T; Inoue H
    Stem Cell Res; 2020 Dec; 49():102095. PubMed ID: 33291009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
    Saeed A; Hoogerland JA; Wessel H; Heegsma J; Derks TGJ; van der Veer E; Mithieux G; Rajas F; Oosterveer MH; Faber KN
    Hum Mol Genet; 2020 Jan; 29(2):264-273. PubMed ID: 31813960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Fructose Diet Increases Renal
    Bier A; Shapira E; Khasbab R; Sharabi Y; Grossman E; Leibowitz A
    Biology (Basel); 2022 Apr; 11(4):. PubMed ID: 35453816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver transplantation for pediatric inherited metabolic liver diseases.
    Vimalesvaran S; Dhawan A
    World J Hepatol; 2021 Oct; 13(10):1351-1366. PubMed ID: 34786171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A triple-blinded crossover study to evaluate the short-term safety of sweet manioc starch for the treatment of glycogen storage disease type Ia.
    Monteiro VCL; de Oliveira BM; Dos Santos BB; Sperb-Ludwig F; Refosco LF; Nalin T; Derks TGJ; Moura de Souza CF; Schwartz IVD
    Orphanet J Rare Dis; 2021 Jun; 16(1):254. PubMed ID: 34082801
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.